Covalon Technologies (COV) AI Stock Analysis

• Market Cap: C$51.37M
• Dividend Yield: N/A
• Average Volume (3M): 17.17K
• Price to Earnings (P/E): 95.7
• Beta (1Y): 0.03
• Revenue Growth: 5.29%
• EPS Growth: -29.02%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 27,618,076
• 10 Day Avg. Volume: 12,083
• 30 Day Avg. Volume: 17,167
• PEG Ratio: -0.88
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 1.75
• P/FCF Ratio: 34.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): C$38.40M

• Rating: 62 Neutral
• Price Target: C$2.00 ▲(14.29% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily supported by improved profitability versus 2022–2023 and strong TTM cash generation alongside low leverage. It is held back by the recent TTM margin and revenue step-down and a high P/E (~51), while technicals are mixed (shorter-term strength but still below the 200-day trend with slightly negative MACD).

Positive Factors

Strong cash generation

Consistent trailing-twelve-month operating and free cash flow of several million dollars provides durable internal funding for working capital, product commercialization and modest R&D. Reliable cash generation improves resilience to revenue swings and supports reinvestment without heavy external financing.

Conservative balance sheet

Very low leverage gives the company long-term financial flexibility to withstand biotech volatility, fund targeted growth initiatives, and absorb temporary revenue pressure. A strong equity cushion reduces refinancing risk and preserves optionality for partnerships or small acquisitions.

Return to profitability

The move from heavy losses to sustained profitability over multiple years signals structural improvements in cost control and product mix. Maintaining positive earnings creates a foundation for predictable cash flow and incremental margin expansion as revenue stabilizes or grows.

Negative Factors

TTM revenue and margin step-down

A recent decline in the trailing revenue run-rate and notable margin compression erode the gains from prior profitability. If weaker demand or pricing pressure persists, cash generation and the ability to scale fixed costs will be strained, increasing execution risk over the next several quarters.

Choppy historical cash flow

Volatile cash conversion history shows cash flow is sensitive to revenue swings and timing. This intermittency reduces the assurance that current TTM cash strength is sustainable, potentially limiting consistent reinvestment, dividend capacity or buffer against unforeseen cost shocks.

Thin current margins

Narrow net and operating margins materially shrink the company’s cushion against cost inflation or reimbursement pressure. With modest operating leverage, small adverse changes in costs or volumes could flip profitability, increasing sensitivity of long-term cash generation and returns.

Covalon Technologies Business Overview & Revenue Model

Company Description

Covalon Technologies Ltd. researches, develops, manufactures, commercializes, and licenses medical technologies and products in the United States, Canada, Europe, the Middle East, Asia, Latin America, and internationally. The company has 3 proprietary platform technologies, including collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; antimicrobial silicone adhesive platform that is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity; and medical coating platform, a proprietary process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. Its products include wound care dressings; surgical and peri-operative products; and infection management products. The company offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. It serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. The company is headquartered in Mississauga, Canada.

How the Company Makes Money

Covalon generates revenue through the sale of its medical products and technologies, primarily targeting hospitals, clinics, and healthcare providers. Its revenue model is based on the direct sale of products, as well as licensing agreements and partnerships with other medical organizations. Key revenue streams include sales of antimicrobial dressings and other wound care products, which are in high demand due to the growing emphasis on infection control in healthcare settings. Significant partnerships with healthcare institutions and distributors also contribute to its earnings, as these collaborations often lead to increased adoption of Covalon's products in various medical environments.

Covalon Technologies Financial Statement Overview

Summary

Improved materially from 2022–2023 losses to profitability in 2024–2025, with strong TTM operating cash flow and free cash flow. Offsetting this, the TTM run-rate weakened (revenue down ~3.9%) and margins compressed meaningfully versus FY2025, indicating higher execution risk if the slowdown persists.

Income Statement

Profitability has improved materially versus 2022–2023 (when losses were substantial), with the business returning to positive earnings in 2024 and remaining profitable in 2025. However, the most recent TTM (Trailing-Twelve-Months) shows a meaningful step-down in profitability versus FY2025 (annual): net margin fell to ~3.1% from ~6.3% and operating margin compressed to ~1.6% from ~6.3%. Revenue is also slightly down in the TTM period (about -3.9%), suggesting the current run-rate is weaker even though gross margin remains solid (~51–53%).

Balance Sheet

The balance sheet looks conservatively financed with low leverage: debt is modest relative to equity (debt-to-equity ~0.07–0.08 in recent periods, and even lower in FY2024). Equity is sizable versus total assets, which provides a cushion for a biotech business that can face volatility. Returns on equity have normalized to mid-single-digits in FY2024–FY2025 and TTM after being sharply negative in 2022–2023, but the recent profitability dip in TTM could pressure returns if it persists.

Cash Flow

Cash generation is a key strength in the latest period: TTM (Trailing-Twelve-Months) operating cash flow (~$7.9M) and free cash flow (~$6.7M) are strong relative to net income, and free cash flow growth is sharply positive. That said, cash flow has been choppy over the cycle (negative operating/free cash flow in 2022–2023 and a softer FY2025 annual operating cash flow compared with earnings), so sustainability depends on maintaining the improved cash conversion seen in TTM.

Breakdown	TTM	Sep 2025	Dec 2024	Dec 2023	Dec 2022	Sep 2021
Income Statement
Total Revenue	31.54M	32.82M	31.17M	26.60M	18.15M	19.56M
Gross Profit	16.28M	17.47M	18.93M	14.36M	7.49M	9.70M
EBITDA	1.44M	3.01M	3.14M	-3.56M	-8.11M	1.54M
Net Income	977.42K	2.06M	2.67M	-4.46M	-9.66M	23.48M
Balance Sheet
Total Assets	32.80M	36.12M	31.81M	24.90M	30.38M	40.58M
Cash, Cash Equivalents and Short-Term Investments	17.88M	17.37M	16.75M	8.79M	14.06M	22.95M
Total Debt	2.07M	2.25M	901.67K	1.56M	2.17M	2.59M
Total Liabilities	6.41M	5.40M	4.30M	6.11M	6.15M	7.21M
Stockholders Equity	26.39M	30.73M	27.50M	18.79M	24.23M	33.37M
Cash Flow
Free Cash Flow	6.68M	1.65M	3.06M	-4.50M	-9.08M	443.71K
Operating Cash Flow	7.92M	2.29M	3.47M	-3.18M	-7.99M	621.37K
Investing Cash Flow	-1.37M	-847.02K	-281.63K	-81.02K	-843.02K	-278.53K
Financing Cash Flow	-4.74M	-529.35K	4.97M	-2.16M	-2.19M	-8.25M

Covalon Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:COV, the sentiment is Positive. The current price of 1.75 is above the 20-day moving average (MA) of 1.71, above the 50-day MA of 1.72, and below the 200-day MA of 2.04, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 61.57 is Neutral, neither overbought nor oversold. The STOCH value of 77.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:COV.

Covalon Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COV	62 Neutral	C$51.37M	95.68	7.07%	―	5.29%	-29.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DTC	45 Neutral	C$35.57M	-6.55	―	―	―	72.92%
SVA	44 Neutral	C$53.87M	-3.13	―	―	―	54.38%
MDNA	42 Neutral	C$56.36M	-4.40	-91.21%	―	―	54.74%
MIR	42 Neutral	C$45.61M	-17.16	―	―	-41.70%	-35.42%

Covalon Technologies Corporate Events

Covalon Posts Near Break-Even Q1 as Clinical Wins and U.S. Contracts Bolster 2026 Outlook

Covalon reported essentially break-even results for its fiscal 2026 first quarter, as revenue declined to $6.9 million from $8.1 million a year earlier and net income fell to $0.1 million, reflecting variability in order timing but supported by a strong balance sheet with $17.9 million in cash and no debt. Management highlighted that sales and orders in early Q2 have already surpassed total Q1 revenue and pointed to accelerating clinical validation, new marquee customers, major U.S. network approvals, and a Vizient-linked contract via partner HARTMANN USA as catalysts that could strengthen growth, enhance industry positioning, and open doors to strategic transactions such as partnerships or M&A.

The company also emphasized growing clinical recognition of its VALGuard vascular access line guard, including peer-reviewed data from a leading U.S. pediatric hospital showing significant reductions in bloodstream infections, which is driving increased customer interest. Educational efforts with vascular access expert Dr. Nancy Moureau and collaborations with professional associations are further elevating awareness of IV line contamination and infection risks, reinforcing Covalon’s role in patient safety solutions and potentially deepening its penetration into large healthcare systems.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Partners with AVA and Dr. Nancy Moureau on IV Infection Prevention Webinar

Covalon Technologies is partnering with the Association for Vascular Access and noted vascular access expert Dr. Nancy Moureau on a continuing education webinar addressing IV line contamination and its role in catheter-associated bloodstream infections. By supporting this accredited training initiative, Covalon seeks to advance evidence-based vascular access practices, reinforcing its positioning as a patient-safety-focused MedTech player and potentially deepening its engagement with clinicians and healthcare institutions.

The webinar, hosted by AVA and led by Dr. Moureau, will explore practical, easy-to-implement interventions to close gaps in infection prevention and improve IV therapy outcomes. This collaboration underscores growing industry emphasis on reducing life-threatening complications from IV therapy, which could bolster adoption of Covalon’s infection-prevention solutions and strengthen its relationships with key stakeholders in the vascular access community.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Sets February 25 Call to Review Q1 Fiscal 2026 Results

Covalon Technologies said it will release its first-quarter fiscal 2026 results before markets open on February 25, 2026, and will host a conference call and webcast at 8:30 a.m. ET the same day to discuss the financial performance. The company will provide a replay of the call on its website and make related financial statements and management discussion documents available through its investor channels, giving stakeholders structured access to its latest financial and operational updates.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Sets Date and Call for Q1 Fiscal 2026 Results

Covalon Technologies plans to release its first-quarter fiscal 2026 results on February 25, 2026, before the market opens and will host a conference call and webcast the same morning to discuss the figures and take questions from participants. The company will also make a recording of the call and related financial documents available to investors online, underscoring its efforts to maintain transparency and engagement with shareholders as it advances its position in the medical technology sector.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Technologies Achieves Record Revenue and Pays First-Ever Dividend

Covalon Technologies reported its highest revenue quarter for fiscal year 2025, marking its third consecutive year of revenue growth. Despite challenges in the market, the company achieved a 5% increase in global revenue to $32.8 million and maintained a strong financial position with $17 million in cash and no debt. Covalon paid its first-ever special dividend, reflecting its robust financial performance. The company also announced the appointment of Katie Martinovich as Chief Financial Officer and secured a new strategic partner for its US Advanced Wound Care sales channel. A recent clinical study on Covalon’s VALGuard® technology demonstrated significant reductions in bloodstream infections, further supporting the adoption of its products.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Technologies Achieves Record Revenue and Strategic Milestones in 2025

Covalon Technologies Ltd. reported its highest revenue quarter of fiscal year 2025, marking its third consecutive year of revenue growth despite global economic challenges. The company achieved a 5% increase in global revenue, totaling $32.8 million, and maintained a strong financial position with $17 million in cash and no debt. Covalon’s strategic advancements include the appointment of a new CFO, securing a significant partnership in the US market, and paying its first-ever dividend, reflecting its robust financial health. Additionally, a peer-reviewed study highlighted the efficacy of Covalon’s VALGuard® technology, contributing to increased adoption and revenue growth in its US sales channels.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.

Covalon Technologies to Announce Fiscal 2025 Financial Results

Covalon Technologies Ltd. has announced that it will release its fourth quarter and year-end fiscal 2025 financial results on December 11, 2025, before the market opens. The company will host a conference call and webcast on the same day to discuss these results, allowing stakeholders to engage with management through a Q&A session. This announcement is significant for stakeholders as it provides an opportunity to gain insights into the company’s financial performance and future outlook.

The most recent analyst rating on (TSE:COV) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Covalon Technologies stock, see the TSE:COV Stock Forecast page.